Results 181 to 190 of about 63,224 (282)

p53; MDM2 [PDF]

Science-Business eXchange, 2008
openaire   +3 more sources

Recent Exploration of Right-Handed D-Sulfonyl-γ-AApeptides as Potential Tools Toward α-Helical Mimicry. [PDF]

Chempluschem
Fontaine J, Cai J.
europepmc   +1 more source

A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Cellular senescence influences cancer progression through irreversible cell‐cycle arrest, immune surveillance, and paracrine signaling mediated by the senescence‐associated secretory phenotype (SASP). SASP comprises inflammatory cytokines, chemokines, growth factors, and matrix‐remodeling enzymes that regulate the tumor ...
Sneha Pallatt, Sibin Nambidi, Antara Banerjee, Surajit Pathak   +3 more
wiley   +1 more source

Garcinoic acid promotes ferroptosis-associated growth inhibition in esophageal squamous cell carcinoma through an MDM2-associated mechanism. [PDF]

Transl Cancer Res
Sun LY, Huang P, Su YH.
europepmc   +1 more source

Mdm2 p53 binding protein homolog (MDM2; HDM2) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin‐proteasome system

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
PRAME promotes SACC invasion and metastasis by inducing EMT via Twist1 upregulation and by destabilizing RARα through Cullin2‑mediated ubiquitination, a mechanism that may limit ATRA efficacy. In vivo, PRAME enhances subcutaneous growth and lung metastasis, highlighting its oncogenic role in SACC.
Xudong Wang, Tingyao Ma, Yixin Jing, Tianyi Li, Xi Zhao, Guohan Zhao, Ran Gao, Lu Kong, Xiaohong Chen   +8 more
wiley   +1 more source

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. Abstract To date, the treatment of acute myeloid leukaemia
Jinlin Zhang, Jile Liu, Mohan Zhao, Xiaoyu Zhang, Linlin Liu, Mengnan Li, Changze Cao, Rui Zhang, Mingfeng Zhao   +8 more
wiley   +1 more source

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. [PDF]

J Clin Invest
Ananthapadmanabhan V, Bruno S, Vonk L, Cheng YC, Teshager A, Eschle BK, Howarth CL, Rodrigues JS, Schnabel J, Kodali A, Gokhale PC, Kshirsagar R, Breitkopf SB, Sharma K, Paulo JA, Li Y, Cherniack AD, Michor F, Chutake Y, Dey J, DeCaprio JA.   +20 more
europepmc   +1 more source

4‐2 VHL‐Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas‐Mediated IL‐17 Signaling

Drug Development Research, Volume 87, Issue 6, September 2026.
ABSTRACT SND1 is an oncoprotein found to be overexpressed in breast cancer, especially in triple‐negative breast cancer(TNBC). In our previous study, a novel SND1‐interacting peptide 4‐2 was identified, exhibiting cytotoxicity to TNBC cells by inducing SND1 degradation.
Qiqi Wang, Qiufeng Huang, Huiping Ou, Tingting Huang, Yunjiao He, Peng Li   +5 more
wiley   +1 more source

GSG2 promotes aerobic glycolysis and colorectal cancer progression via the MDM2-p53 axis. [PDF]

Am J Cancer Res
Pan H, Liu J, Xiao T, Huang J.
europepmc   +1 more source